Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substan
Addiction problems to psychoactive substances are becoming more frequent, which implies a serious health problem, with social, family and work repercussions. Participants with chronic consumption present important degeneration processes mediated by Neuroinflammation, oxidative stress and excitotoxicity. At the moment t
| Condition(s) | Addiction;Drug(S);LSD, Neuroprotective |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Addiction problems to psychoactive substances are becoming more frequent, which implies a serious health problem, with social, family and work repercussions. Participants with chronic consumption present important degeneration processes mediated by Neuroinflammation, oxidative stress and excitotoxicity. At the moment there is no effective treatment that can reduce the damage. The effectiveness of Omega 5 has been demonstrated in different disorders of the nervous system; However, very little has been elucidated about the mechanisms of regulation and activation in consumer patients. Omega 5 Nano-PSO has an important role in mechanisms of cell survival in different pathological events. In this project aims to explain the possible mechanisms underlying the morphological changes and pathologie |
| Who can participate | Inclusion Criteria: * Patients who are multiple users of methamphetamines, cocaine, and cannabis with or without alcohol and tobacco, and have a history of at least 3 years of consumption. * Patients who accept informed consent to participate in the protocol. * Male gender. * Age between 18-50 years in the withdrawal phase currently in residential treatment Exclusion Criteria: * Individuals under 18 years of age. * Patients who do not sign the informed consent. * Discharge of patients prior to the stipulated 6 months, requested by family members. * Patients with developed or known allergies. * Patients who are consuming NSAIDs, MAOIs (monoamine oxidase Inhibitor), active chronic inflammatory diseases, or any type of cancer |
| Ages | 18 Years to 50 Years |
| Sex | Male |
| Lead sponsor | Distribuidora Biolife SA de CV |
| Locations | Guadalajara, Jalisco, Mexico |
| Start date | 2024-03-15 |
| NCT ID | NCT06550167 |
| Official listing | https://clinicaltrials.gov/study/NCT06550167 |